NasdaqGS - Delayed Quote • USD
Seres Therapeutics, Inc. (MCRB)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 7:54 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 6 |
| Avg. Estimate | -0.34 | -0.31 | -1.14 | -0.8 |
| Low Estimate | -0.43 | -0.39 | -1.57 | -1.46 |
| High Estimate | -0.26 | -0.2 | -0.8 | -0.37 |
| Year Ago EPS | -0.57 | 0.36 | -0.89 | -1.14 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 5 |
| Avg. Estimate | 250k | 250k | 1.36M | 9.17M |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | 1.5M | 1.5M | 6M | 39.84M |
| Year Ago Sales | 1.38M | 126.47M | 126.33M | 1.36M |
| Sales Growth (year/est) | -81.90% | -99.80% | -98.90% | 574.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.55 | 0.53 | -0.5 | -0.5 |
| EPS Actual | -0.57 | 0.36 | -0.37 | -0.32 |
| Difference | -0.02 | -0.17 | 0.13 | 0.18 |
| Surprise % | -3.60% | -32.10% | 26.00% | 36.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.34 | -0.31 | -1.14 | -0.8 |
| 7 Days Ago | -0.34 | -0.31 | -1.14 | -0.8 |
| 30 Days Ago | -0.34 | -0.31 | -1.14 | -0.8 |
| 60 Days Ago | -0.37 | -0.33 | -1.37 | -0.72 |
| 90 Days Ago | -0.37 | -0.33 | -1.36 | -0.71 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | MCRB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 40.40% | -- | -- | 1.50% |
| Next Qtr. | -186.10% | -- | -- | 11.40% |
| Current Year | -28.10% | -- | -- | 5.20% |
| Next Year | 29.80% | -- | -- | 13.40% |
| Next 5 Years (per annum) | -134.00% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Oppenheimer: Outperform to Outperform | 3/6/2024 |
| Maintains | Chardan Capital: Buy to Buy | 3/6/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 1/16/2024 |
| Maintains | Goldman Sachs: Sell to Sell | 11/3/2023 |
| Maintains | Chardan Capital: Buy | 4/28/2023 |
| Initiated | JP Morgan: Neutral | 4/21/2023 |
Related Tickers
AKBA Akebia Therapeutics, Inc.
1.3700
0.00%
DAWN Day One Biopharmaceuticals, Inc.
15.19
-8.71%
XFOR X4 Pharmaceuticals, Inc.
1.2900
+4.88%
PDSB PDS Biotechnology Corporation
3.2500
+1.56%
TGTX TG Therapeutics, Inc.
13.98
-1.89%
ABEO Abeona Therapeutics Inc.
3.1700
-7.04%
ARDX Ardelyx, Inc.
6.43
+0.63%
CDTX Cidara Therapeutics, Inc.
12.29
+19.90%
KPTI Karyopharm Therapeutics Inc.
1.0900
0.00%
IOVA Iovance Biotherapeutics, Inc.
11.71
-1.26%